Summer Sale
50% off Premium Yearly
NASDAQ:TRDA
Entrada Therapeutics, Inc. (TRDA)
Financials 
Technical Analysis 
;fill-opacity:1;'/%3e%3cpath%20d='M31%2018.6001V30H8V18.6001L14.1334%2022.4334L19.4999%2014L24.8669%2022.4334L31%2018.6001Z'%20fill='%23EE5432'%20style='fill:%23EE5432;fill:color(display-p3%200.9340%200.3310%200.1956);fill-opacity:1;'/%3e%3c/svg%3e){kind=small}
Premium contentPremium contentThis pharma company produces clinical stage drugs that aid the delivery of other therapeutics and they have been advancing a portfolio of RNA based programs. It trades at 6x trailing earnings, under 1.5x book and supports a 32% ROE and has growing cash reserves. We recommend setting a stop-loss at $13, looking to achieve $21 -- upside potential of 27%. Yield 0%
(Analysts’ price target is $21.50)- «
- ‹
- 1
- ›
- »
Entrada Therapeutics, Inc. (TRDA) Frequently Asked Questions
What is Entrada Therapeutics, Inc. stock symbol?
Entrada Therapeutics, Inc. is a American stock, trading under the symbol TRDA (previously TRDA-Q on Stockchase) on the NASDAQ (TRDA). It is usually referred to as NASDAQ:TRDA or TRDA
Is Entrada Therapeutics, Inc. a buy or a sell?
In the last year, no analyst issued a Buy, Sell, or Hold rating on TRDA (previously TRDA-Q on Stockchase) on Stockchase. Read the latest expert commentary for Entrada Therapeutics, Inc..
Is Entrada Therapeutics, Inc. a good investment or a top pick?
Entrada Therapeutics, Inc. was recommended as a Top Pick by The Panic-Proof Portfolio (Stockchase Research) on 2024-10-08. Read the latest stock experts ratings for Entrada Therapeutics, Inc..
Why is Entrada Therapeutics, Inc. stock dropping?
Earnings reports or recent company news can cause the stock price to drop. Read stock experts' recommendations for Entrada Therapeutics, Inc..
Is Entrada Therapeutics, Inc. worth watching?
Entrada Therapeutics, Inc. is covered by Stockchase experts and is worth watching.
What is Entrada Therapeutics, Inc. stock price?
On 2026-06-12, Entrada Therapeutics, Inc. (TRDA) stock closed at a price of $6.46.
Our PAST TOP PICK with TRDA has triggered its stop at $16. To remain disciplined, we recommend covering the position at this time. This will result in a net investment gain of 12%, when combined with our previous guidance.